Objective To evaluate gender differences in GH dosing, IGF-I and cardiovascular risk markers in adults with GH deficiency (GHD). Design NordiNet â International Outcome Study (NCT00960128), a noninterventional, multicentre study, evaluates the long-term effectiveness and safety of Norditropin â (Novo Nordisk A/S) in the real-life clinical setting. Patients Nondiabetic patients (n = 252; 41Á7% female) with adult-onset GHD (age ≥20 years at GH start), ≥4 years' GH therapy and glycosylated haemoglobin (HbA 1c ) data at baseline and 4 years. Measurements Effects of gender (adjusted for baseline age and body mass index [BMI], average GH dose, treatment duration and concomitant medication) on change from baseline to 4 years (Δ) in HbA 1c , fasting plasma glucose (FPG), IGF-I, lipids and waist circumference were evaluated. Results GH dose (mean [SE]; mg/day) was similar between females (0Á22 [0Á02]) and males (0Á21 [0Á01]) at baseline, but higher in females from year 1 (year 4, females, 0Á45 [0Á03]; males, 0Á32 [0Á02]). Mean IGF-I standard deviation score [SDS] was lower in females vs males at each treatment year; more than onethird of females still had an IGF-I SDS below 0 at year 4, compared with only 21Á8% of men. An adverse lipid profile at baseline remained poor in more females than males at 4 years. Improvement in total cholesterol was significantly associated with gender (P < 0Á0001), improving less in females than in males. Conclusions These data highlight that, even after 4 years, GH dose is suboptimal in many female patients, which may impact clinical outcomes; therefore, GH titration for women requires further improvement.
Introduction
The goal of GH replacement therapy in adults with GH deficiency (GHD) is to correct a wide spectrum of clinical alterations associated with adult GHD, including metabolic, physical and psychological problems. 1 Untreated GHD in adults is associated with an increased cardiovascular risk; risk factors include dyslipidaemia, manifested as raised levels of low-density lipoprotein cholesterol (LDL-C) and triglycerides, and reduced levels of high-density lipoprotein cholesterol (HDL-C), 2 increased body fat and reduced insulin sensitivity. 3 Mortality resulting from cardiovascular disease is higher in hypopituitary adults with GHD and organic pituitary disease than in the general population [4] [5] [6] and may be higher in women than in men. [4] [5] [6] [7] International treatment guidelines recognize that GH dose must be individualized to account for variations in physiological GH secretion resulting from interindividual differences in GH sensitivity dependent on age, gender and other baseline characteristics. [7] [8] [9] Recently published guidelines from the Endocrine Society for treating patients with hypopituitarism recommend a lower starting dose for older (≥60 years) vs younger patients (<60 years). 10 Clinical guidelines and guidance in the GH manufacturers' product labels suggest that a low starting dose should be increased gradually based on the patient's clinical response, the occurrence of adverse events and aiming for serum IGF-I levels in the upper half of the normal range appropriate for age and gender 8, 10, 11 with an associated optimal level of physical and psychological functioning. 7, 9, 12 Although GH production is almost twofold higher in healthy females vs males, IGF-I levels are similar, suggesting that females are less responsive to GH than males. 13 The difference between genders is attributed to the GH-antagonistic properties of oestrogen [14] [15] [16] and suppression by oral oestrogen of hepatic IGF-I production, 17 but may also be influenced by testosterone generating higher IGF-I levels. 14 In contrast to healthy adults, IGF-I levels are lower in untreated females with GHD vs males with GHD. 14 Gender differences in physical clinical responses to GH such as body composition 18, 19 and bone density 20 have also been reported. Adjustment for baseline factors such as age and body mass index (BMI) attenuates the apparent gender difference in responsiveness to GH, but this difference also depends on the metrics used for assessing outcomes such as body composition. 21 Nevertheless, females require higher doses of GH than males to achieve the same clinical responses and IGF-I levels; this is formally reflected in guidelines. [7] [8] [9] The aim of this analysis was to evaluate real-world gender differences in GH dosing and associated changes in IGF-I levels and clinical markers for cardiovascular prognosis during 4 years' GH replacement in adults with GHD enrolled in the NordiNet 
Patients and methods

Patients
Nondiabetic GH treatment-na€ ıve adult patients with GHD (age ≥20 years at GH treatment start; diagnosed according to international clinical guidelines 9 ) enrolled in NordiNet â IOS, treated for ≥4 years with Norditropin â (somatropin) (Novo Nordisk A/S, Søborg, Denmark) with baseline, and 4-year glycosylated haemoglobin (HbA 1c ) data were included in the analysis. The diagnosis and treatment of patients enrolled in the study were carried out according to local clinical practice. Hence, the diagnostic approach used and the decision to administer GH were at the discretion of the investigating-site physician. Patients diagnosed with diabetes, receiving antidiabetic treatment or with HbA 1c >6Á5% at baseline were excluded from the present analysis. The decision to exclude patients with diabetes from the study population was made to ensure that the study results were not affected by the comorbidities or, more importantly, by the concomitant medications prescribed and to ensure that any observed effects of GH therapy on parameters of glucose metabolism were not confounded by any antidiabetic treatment. All patients provided written informed consent prior to study enrolment. The study was conducted in accordance with the Declaration of Helsinki. Approval by the local Ethics Committee/Institutional Review Board at the individual centre level in accordance with country-specific rules and data privacy agencies is a prerequisite for each centre's inclusion in NordiNet â IOS.
NordiNet â IOS is conducted in accordance with the Good Pharmacoepidemiology Practice guidelines. 22 
Study design
The 
Results
Qualifying data were available and analysed for 252 patients (41Á7% female) ( Table 1) . Data on BMI were available for 95 (90Á5%) females and 139 (94Á6%) males; 62Á1% of females and 81Á3% of males had BMI ≥25 kg/m 2 at baseline (Table 1) . Overall, 30Á8% (24 of 78) of females aged <55 years and 14Á8% (four of 27) of females aged ≥55 years were reported as receiving sex hormones at baseline. Data on the aetiology of GHD for patients included in the analyses with available data are shown in Table S1 . The most common cause of GHD among patients with available data was a pituitary tumour. The next most frequent aetiologies were nonfunctioning pituitary adenoma, pituitary adenoma and congenital GHD ( Table S1 ). Note that it was not mandatory to report such data, and therefore data are missing for 30 of 252 (12%) patients.
GH dose and IGF-I SDS
GH dose and IGF-I SDS at baseline, and by treatment year and gender, are shown in Fig. 1 . GH dose was similar between genders at baseline, but after the first year females tended to receive larger daily doses than males (Fig. 1a) . The mean (SD) increase in GH dose from baseline to year 4 was 0Á22 (0Á25) mg/day in females and 0Á10 (0Á14) mg/day in males. Mean IGF-I SDS was <0 at baseline and increased to ≥0 by year 1 in both genders, remaining at this level for the remainder of the study period. However, although estimated mean (SE) ΔIGF-I SDS was the same in both genders (1Á57 [0Á1]), mean IGF-I SDS appeared to be lower for female vs male patients at baseline and each treatment year (Fig. 1b) .
Multiple regression analysis showed a statistically significant association between gender and ΔIGF-I SDS during 4 years of treatment (Table 2) , reflecting the slower increase in IGF-I SDS in females than in males (Fig. 1b) . Age at treatment start, but not GH dose or BMI, was associated with ΔIGF-I SDS, with change from baseline to 4 years being greater in patients who were older at treatment start vs those who were younger.
The proportion of males with IGF-I SDS ≥0 rapidly increased after initiation of GH therapy: 74Á2% of males achieved this level by year 1 (Fig. 2a) . In contrast, only 53Á4% of females achieved this level by year 1 and 64Á7% by year 2, with no further increase thereafter (Fig. 2a) . After 4 years' GH therapy, 37Á1% of females had IGF-I SDS <0. The proportions of males aged <55 and ≥55 years who achieved target IGF-I SDS appeared to be similar at each treatment year (Fig. 2b) . Among females aged <55 years, 88Á5% had IGF-I SDS <0 at year 1 and 42Á3% had IGF-I SDS <0 at year 4. For patients aged >55 years, the respective proportions at year 1 and year 4 were 88Á9% and 22Á2% (Fig. 2b) .
Metabolic parameters
All mean baseline and 4-year HbA 1c and FPG values were in the normal range.
Overall, HbA 1c was similar for both genders with normal BMI at baseline and 4 years (Fig. 3a) , with no clinically relevant change from baseline across this interval in either gender. Among female patients with obesity, there appeared to be a trend towards more elevated values of HbA 1c at year 4 than in patients with normal BMI. In male patients with obesity and overweight, a trend to higher values of HbA 1c was seen at baseline and 4 years compared with male patients with normal BMI. The regression analysis did not show any association between gender and ΔHbA 1c ; however, a significant association with BMI was seen, confirming the significantly greater increase in HbA 1c in patients with obesity vs those with normal BMI or with overweight (P = 0Á002) ( Table 2 ). No significant difference was shown between patients with overweight and those with normal BMI. ΔHbA 1c was also significantly associated with age at treatment start and GH dose, with ΔHbA 1c being greater in patients who were older at baseline and in those receiving lower GH doses than in younger patients or those receiving higher GH doses (Table 2) . Statistical significance was not reached for the adjustment by glucocorticoid supplementation (P = 0Á059) or antidiabetic treatment in the model (P = 0Á367).
Seven patients developed diabetes during the first 4 years, four of whom had impaired glucose tolerance at baseline. Among patients with obesity, HbA 1c tended to be higher among males than females (Fig. 3a) . 
Data presented in the table are the EE, SE and P-value of the parameters listed on change from baseline up to year 4 for each respective end-point. The estimated effect indicates the magnitude of the explanatory value of each parameter in the model. EE, estimated effect; FPG, fasting plasma glucose; HbA 1c , glycosylated haemoglobin; HDL-C, high-density lipoprotein cholesterol; IGF-I, insulin-like growth factor-I; LDL-C, low-density lipoprotein cholesterol; SDS, standard deviation score; SE, standard error; TC, total cholesterol. *Female patients were compared with male patients as reference. FPG levels in females tended to be lower than those observed in males at baseline, but appeared similar between female and male patients at year 4 ( Fig. 3b) , with a slight increase in average in both genders (estimated mean [SE] change from baseline: females, 0Á45 [0Á09]; males, 0Á21 [0Á09]). ΔFPG was independent of gender, BMI (Table 2) or glucocorticoid treatment (P = 0Á052). Antidiabetic treatment did not have a statistically significant influence on the results. However, statistically significant associations were found between ΔFPG and GH dose and age at treatment start (Table 2) , with ΔFPG being greater in patients who were older at baseline and those receiving lower average GH doses vs those who were younger or receiving higher average GH doses.
Lipids
Baseline mean levels of TC were above ideal levels (<5Á2 mmol/l [<200Á7 mg/dl]) 28 in both genders (Table 1) . After 4 years' GH treatment, there was a trend to a greater decrease from baseline in estimated mean (SE) TC levels in males (-0Á41 [0Á08] mmol/l) vs females (-0Á11 [0Á12] mmol/l) (Fig. 4a) ; however, estimated mean (SE) TC levels at year 4 remained high (females, 5Á75
[0Á12] mmol/l; males, 5Á26 [0Á08] mmol/l). Multiple regression analysis confirmed a significant association between ΔTC and gender in favour of males (Table 2 ). An inverse association was found between ΔTC and GH dose, with patients receiving lower average GH doses experiencing a smaller decrease in TC than those receiving higher average GH doses. No significant association between ΔTC and age at treatment start or BMI was found (Table 2) , but there was a significant inverse association between ΔTC and concomitant lipid-lowering treatment (estimated effect, -0Á670; P = 0Á0001).
Mean LDL-C/HDL-C was at or near cut-off risk levels (females, ≤3Á0; males, ≤3Á5) 29 at baseline and throughout the study for all male patients and for female patients with normal BMI (data not shown). However, this ratio was high at baseline for females with overweight and increased to above cut-off risk levels in females with obesity at 4 years (Fig. 4b) . ΔLDL-C/HDL-C was not associated with gender (Table 2) , but a significant overall association with BMI was seen (P = 0Á014) with a significantly greater change from baseline in patients with obesity vs those with overweight or normal BMI (Table 2 ), but did not differ between patients with normal BMI and those with overweight. ΔLDL-C/HDL-C was inversely associated with both age at treatment start and GH dose ( Table 2 ), suggesting that among patients who were younger at baseline or on lower average GH doses, the increase in LDL-C/ HDL-C from baseline was greater or there was less of a decrease than among patients who were older or receiving higher GH doses. The lipid-lowering treatment adjustment did not reach statistical significance in the model (P = 0Á092). Mean baseline and 4-year fasting triglyceride levels were above normal levels (1Á13-1Á7 mmol/l [100Á0-150Á4 mg/dl]) for females but not males (Fig. 4c) . At 4 years, estimated mean (SE) triglyceride levels had increased slightly from baseline in females and decreased from baseline in males (Fig. 4c) ; however, regression analysis showed no significant association between Δ triglycerides and gender (P = 0Á854), BMI (Table 2) or lipid-lowering treatment (P = 0Á982). A weak but statistically significant inverse association between Δ triglycerides and age at treatment start and GH dose was shown, with a higher increase or less decrease in triglycerides from baseline among patients who were younger at treatment start or receiving lower GH doses vs those who were older or receiving higher GH doses ( Table 2) . The proportions of patients with abnormal lipid levels 28, 30 at baseline and after 4 years' GH treatment were evaluated descriptively by gender. High TC levels (>6Á2 mmol/l [240 mg/dl]) were found in 29 (31Á2%) females and 36 (27Á7%) males at baseline, with these proportions appearing to decrease at 4 years in both genders when 14Á0% of male and 25Á9% of female patients were assessed as having abnormal TC levels. Poor HDL-C levels ((females <1Á3 mmol/l [50 mg/dl]); males <1Á0 mmol/l [<40 mg/dl]) were found in 38Á3% of females and 24Á0% of males at baseline, with these proportions remaining relatively unchanged at 4 years (females, 44Á1%; males, 21Á2%). Poor LDL-C levels (≥4Á1 mmol/l [≥160 mg/dl]) were observed in similar proportions of females at baseline and 4 years (25Á0% vs 25Á3%). These proportions were 31Á2% and 13Á4%, respectively, for males. No clear relationship was observed between target IGF-I SDS (≥0) and the proportions of patients by gender with suboptimal lipid levels (data not shown).
Waist circumference
Although estimated mean (SE) waist circumference appeared to be smaller in female vs male patients at baseline and 4 years ( Fig. 4d ), levels were more elevated above the clinically defined cut-off points for clinical intervention for females (88 cm) than males (102 cm) 31 at both time points. Overall, waist circumference decreased slightly more from baseline to 4 years in females
. Regression analysis did not show an association between Δ waist circumference and gender or age at treatment start, but there was an inverse association with GH dose such that patients receiving higher GH doses experienced a greater decrease/smaller increase in waist circumference than those receiving lower GH doses (Table 2) .
Discussion
The present analysis of a multinational cohort of patients with adult-onset GHD confirms the higher GH dose requirement of females vs males. We also showed that, in contrast to published clinical guidelines, GH was initiated at similar doses in both males and females. The recommended starting dose in the international consensus guidelines is 0Á2 mg/day in males and 0Á3 mg/day in females, 9 whereas more recent guidance from the Endocrine Society concerning treatment of adult patients with hypopituitarism recommends a starting dose of 0Á2-0Á4 mg/day for patients aged under 60 and 0Á1-0Á2 mg/day for patients older than 60 years 10 ;
in comparison with both of these recommendations, the initially prescribed GH dose in this population was suboptimal in females. Over subsequent years, the mean (SD) GH dose was increased to a greater degree in females vs males but, despite this, over one-third of females had not achieved target IGF-I SDS (≥0) 8 at year 4, suggesting that for many females GH dose may be suboptimally titrated. Overall, the increase in IGF-I SDS appeared to be slower in females, supporting previous evidence that females are less sensitive than males to the effects of GH. However, as proportionally more older than younger females achieved IGF-I SDS ≥0 and as fewer older than younger females were likely to be receiving sex hormone replacement therapy, this finding may support the view that higher doses of GH are required to achieve the same IGF-I SDS levels in females who are premenopausal or receiving oral oestrogen therapy vs postmenopausal females, or those receiving transdermal oestrogen therapy or no oestrogen treatment at all. 32 This observation, however, was not evaluated further in our data because of the limited availability of data on concomitant sex hormone therapy.
We found a small overall improvement in the lipid profile after 4 years' GH therapy. Baseline lipid levels were indicative of an impaired lipid profile and a less favourable cardiovascular risk profile at treatment start in females vs males. Although regression analysis identified gender as only being associated with ΔTC, with the direction of change favouring males, we observed a trend to a slightly greater improvement in triglycerides in males vs females, as well as marked differences between genders among patients with elevated BMI with respect to Δ LDL-C/HDL-C and in the increased proportions of females vs males with poor TC, HDL-C and LDL-C levels. The LDL-C/ HDL-C ratio remained poor in females with obesity, but improved in males with overweight or obesity, and proportionally fewer males than females had abnormal lipid levels at 4 years vs baseline. A possible explanation for the observed absence of a statistically significant association between gender and change in LDL-C/HDL-C and triglycerides in the regression analysis was the significant deviations of these parameters from the mean and the low number of observations.
Mean HbA 1c and FPG remained relatively stable and were unchanged from baseline, remaining within the normal range at 4 years. No association between ΔHbA 1c or ΔFPG with gender was shown, but there was a close to significant relationship between concomitant glucocorticoid supplementation and ΔHbA 1c and ΔFPG. The seven patients who developed diabetes during the 4 years of GH treatment in the present analysis were also included in an earlier report which showed that these patients tended to be older, to be receiving a lower GH dose and to have a more elevated BMI at baseline vs the total cohort. 33 No gender association was found for change in waist circumference, which may be considered to reflect visceral adiposity, although GH dose was significantly associated with this parameter.
Results of our study are consistent with published data on the effects of long-term GH replacement on cardiovascular risk factors. Consistent with our data, most published studies do not show an effect of gender on serum lipids or glycaemic parameters, 34, 35 although similar to our study, Elbornsson et al. documented a greater decrease in TC in males than in females when females received a higher GH dose than males. 36 However, our data extend these findings to show that proportionally more females than males had abnormal levels of the lipid parameters assessed after 4 years' GH treatment and that 37% (57Á7% aged <55 years) of females did not achieve target IGF-I SDS after 4 years' GH therapy, suggesting that some patients, particularly younger females, may not gain optimal benefit from GH replacement as currently administered. There may also be a higher proportion of females than males with elevated BMI who do not respond as well to the effects of GH therapy. This suggests that attention should be paid to indices of cardiovascular risk in female patients, particularly those with BMI above the normal range.
There are a number of limitations to our study. Given that there was no control group, it could not be assessed whether GH therapy impacted the measured parameters, which might otherwise have evolved differently over the 4-year study period. Other endpoints affected by GH therapy (e.g. bone mineral density, body composition) might have given clearer indications of response to therapy and of gender differences, but these data were not systematically recorded. Measurement of metabolic parameters by local laboratories rather than in a central facility may represent another limitation. Nevertheless, as the study reported changes over time in study outcomes, with longitudinal outcomes for each patient being most probably measured at the same laboratory using the same references throughout the study period, it is likely that the observed changes in study parameters reflect actual trends and would not be affected by intercentre differences of assays used. As is common with an observational study design, concomitant medication use was not controlled, and data on use of concomitant medication, including lipid-lowering medication or sex hormone therapy, were not systematically collected. Therefore, it was not possible to systematically evaluate the impact of these concomitant therapies on the study end-points. It is well known that adherence or nonadherence to treatment can have a significant impact on effectiveness outcomes. However, measures of adherence were not reported during the follow-up period in our study, so the impact of adherence on the reported end-points was not assessed. Finally, as this is an observational study, data captured may be incomplete, and therefore observed associations should be interpreted with caution.
In conclusion, our data from a real-world setting show that during 4 years' GH therapy, although females with adult-onset GHD received higher GH doses than males, the initiation and titration of GH dose remained suboptimal for a considerable proportion of females, especially those aged <55 years. Overall, one-third of females failed to achieve published target IGF-I SDS ≥0 after 4 years treatment. An adverse lipid profile was found in one quarter of females after 4 years' GH therapy compared with a much lower proportion of males, suggesting that attention should be paid to indices of cardiovascular risk in female patients, particularly in those with elevated BMI. This study highlights for the first time that suboptimal titration of GH may adversely affect clinical outcomes in a proportion of female patients with GHD; these findings underline the need for appropriate GH dose individualization, particularly in females, and strongly support current guideline recommendations to initiate GH substitution at higher doses in women than men.
